

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
AMYL-A 3 of 5 Internal request: Comment to consider the inclusion of the following as an option for Previously Treated Disease: <ul style="list-style-type: none"> Ixazomib/lenalidomide/dexamethasone Comment to consider the inclusion of the following as options under Useful in Certain Circumstances for Previously Treated Disease: <ul style="list-style-type: none"> Bendamustine/dexamethasone Carfilzomib for non-cardiac amyloidosis ± dexamethasone Venetoclax t(11;14) ± dexamethasone 	Based on the review of the data in the noted reference, the panel consensus was to include Ixazomib/lenalidomide/dexamethasone as an option for previously treated disease. This is a category 2A recommendation. Reference: <ul style="list-style-type: none"> Cohen OC, Sharpley F, Gilmore JD, et al. Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis. Br J Haematol 2020;189:643-649. 	23	0	0	8
	Based on the review of the data in the noted references below, the panel consensus was to include the following as options under useful in certain circumstances for previously treated disease. These are category 2A recommendations. <ul style="list-style-type: none"> Bendamustine/dexamethasone 	23	0	0	8
	<ul style="list-style-type: none"> Carfilzomib for non-cardiac amyloidosis ± dexamethasone 	23	0	0	8
	<ul style="list-style-type: none"> Venetoclax t(11;14) ± dexamethasone References: <ul style="list-style-type: none"> Lentzsch S, Lagos GG, Comenzo RL, et al. Bendamustine with dexamethasone in relapsed/refractory systemic light-chain amyloidosis: Results of a phase II study. J Clin Oncol 2020;38:1455-1462. Manwani R, Mahmood S, Sachchithanantham S, et al. Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. Br J Haematol 2019;187:638-641. Premkumar VJ, Lentzsch, Pan S, et al. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer J 2021;11:10. 	23	0	0	8